PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · IEX Real-Time Price · USD
2.83
+0.08 (2.91%)
At close: Aug 17, 2022 4:00 PM
2.76
-0.07 (-2.47%)
After-hours: Aug 17, 2022 6:07 PM EDT
2.91%
Market Cap 58.72M
Revenue (ttm) n/a
Net Income (ttm) -4.24M
Shares Out 20.75M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 138,695
Open 2.75
Previous Close 2.75
Day's Range 2.74 - 2.89
52-Week Range 1.79 - 9.98
Beta 0.00
Analysts Sell
Price Target n/a
Earnings Date Sep 13, 2022

About PMCB

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and ... [Read more...]

Industry Biotechnology
Founded 1996
Employees 4
Stock Exchange NASDAQ
Ticker Symbol PMCB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Sell
Stock Forecasts

News

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live...

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

Reiterates its Belief that the Root Cause of the Company's Problems is an Insular and Dysfunctional Board Comprised of Chairman and CEO Kenneth Waggoner's Entrenched Management Team and Unqualified, Han...

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live...

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live...

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

LAS VEGAS--(BUSINESS WIRE)--Preliminary Financial Results for Fiscal Year 2022 are announced by PharmaCyte Biotech, Inc.

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

NEW YORK , July 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a written consent to  ...

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

NEW YORK , July 5, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or ...

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-...

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEE...

Believes Truly Independent Board Required to Increase Accountability Given PharmaCyte's Long History of Missed Milestones Highlights Severe Governance Deficiencies and Recent Half-Baked Efforts to Appea...

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its si...

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its si...

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

Believes the Company's Recently Announced Initiatives are a Reactionary and Transparent Attempt to Placate Stockholders by Conveniently Implementing a Few of Iroquois' Long-Standing Recommendations With...

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its s...

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock.

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signatu...

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the Co...

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte's management team is attending the 15th International Conference on Advanced Technologies and Treatment for Diabetes in Barcelona, Spain.

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate t...

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces another positive test result. The result shows that CypCap material does not cause systemic toxicity.

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signatu...

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation ...

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech successfully completed a 24-month stability study of its clinical trial product candidate.

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech reports positive third quarter results and operational highlights.

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte announces genetic stability of the cytochrome P450 gene and site of integration for its pancreatic cancer product candidate.

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech updates status of its Investigational New Drug Application to the FDA.